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Diffuse large B-cell lymphoma represents 30-40% of all 
non-Hodgkin lymphomas in Western countries (1). Tu-
mor cells are peripheral lymphocytes from germinal cen-
ters or a postgerminative stage of B-cell development. 
Very high percentage of the cells express BCL6, with 30-
50% cases showing the expression of BCL2 protein. 3q27 
region abnormalities, with the most likely candidate be-
ing the BCL6 gene, are detected in 30% of the cases. The 
Prognostic Markers and Gene Abnormalities in Subgroups of Diffuse 
Large B-cell Lymphoma: Single Center Experience
Aim To explore the association between FOXP1, BCL2, and BCL6 
gene expression in diffuse large B-cell lymphoma tumor cells and their 
association with the presence of FOXP3 lymphocytes.
Methods Samples of lymph nodes from 53 patients with newly diag-
nosed diffuse large B-cell lymphoma were taken at the time of the diag-
nosis and immunostained for CD10, MUM1, BCL6, BCL2, FOXP1, 
and FOXP3. Fluorescent in situ hybridization analysis was used for the 
detection of FOXP1, BCL2, and BCL6 gene abnormalities. The χ2 test 
was used for data analysis.
Results FOXP1 protein was detected in 28 cases, genetic abnormali-
ties involving the FOXP1 locus were found in 19 cases, and both were 
present in 13 cases (χ2 =7.157; P = 0.028). FOXP3 positive cells were 
detected in 37 cases. There was a significant relationship between BCL2 
expression and FOXP1 genetic abnormalities (χ2 =5.858; P = 0.016) 
and between BCL2 expression and BCL2 genetic abnormalities 
(χ2=6.349; P = 0.012). There was also an association between BCL6 
and FOXP1 genetic abnormalities (χ2 =8.497; P = 0.004).
Conclusion Association was observed between additional FOXP1 
gene copies and BCL2 protein expression as well as changes on both 
FOXP1 and BCL2 genes in samples of our DLBCL patients.. FOXP3 
positive cells showed no association with presence of any of analyzed 
proteins considered as a prognostic markers in DLBCL neither with 
changes of their genes.
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IgH/BCL2 - t(14;18)(q32;q21) translocation 
is known to be the oncogenic event underly-
ing the development of follicular lymphoma 
and is seen in 20-30% of cases of diffuse large 
B-cell lymphoma (1). Diffuse large B-cell lym-
phoma shows heterogeneity of its genetic ab-
normalities and cell type of origin. Many au-
thors have tried to divide diffuse large B-cell 
lymphoma into groups according to its rela-
tionship to normal B-cell counterparts shar-
ing a common gene expression profile (1). The 
currently accepted subgroups include the ger-
minal center (GC)-like cells subgroup, acti-
vated B cell (ABC)-like subgroup, and a third 
subgroup named simply “type 3,” representing 
all the diffuse large B-cell lymphoma cases that 
cannot be specified as either GC or ABC sub-
group (2-6).
There is a lack of predictive markers that 
can be reliably and robustly applied to rou-
tine diagnosis of diffuse large B-cell lympho-
ma. Some studies found that BCL2 and BCL6 
proteins have an impact on diffuse large B-cell 
lymphoma development and outcome, but 
there is debate as to whether they can be used 
as good prognostic markers (1). Other stud-
ies have shown that overexpression of FOXP1 
protein has an impact on diffuse large B-cell 
lymphoma development (7-9). In normal tis-
sue, FOXP1 expression was observed in scat-
tered cells in germinal centers, in most cells 
of the mantle zone, and in a few B-cells in the 
T-cell zone (10). It was found to have stron-
ger expression following B-cell activation (11), 
to be an essential transcriptional regulator for 
early B-cell development (12), and to influence 
RAG expression (13). In tumor cells, FOXP1 
shows loss of expression, cytoplasmic localiza-
tion, or overexpression (10). Translocation of 
the FOXP1 gene has been demonstrated in ex-
tranodal B-cell lymphoma of marginal zone of 
MALT type and other B-cell non-Hodgkin 
lymphomas (14-16).
Other members of FOXP family are also 
known to have a role in tumorigenesis. FOXP3 
mutations can cause IPEX syndrome (immune 
deregulation, polyendocrinopathy, enteropa-
thy, X-linked syndrome) (17,18). This gene 
has been recently recognized as a significant 
factor in the regulation of T-cell activation 
(19) and as an important gene for the devel-
opment of regulatory T-lymphocytes (20,21). 
FOXP3 immunostaining can be used for de-
tection of Treg cells (22) and has been used for 
analyzing the correlation between the number 
of Tregs and the prognosis in follicular lym-
phoma patients (23,24).
In this study, we investigated the expres-
sion and genetic abnormalities of BCL2, 
BCL6, and FOXP1 genes in Croatian patients 
with diffuse large B-cell lymphoma from a sin-
gle hematopathology center. Our aim was to 
determine the association between FOXP1 
and BCL2, as previously described by Ban-
ham et al (8) and Barrans et al (7), and the dif-
ferences in this association between GC and 
ABC subgroup of diffuse large B-cell lympho-
ma. We were especially interested in the as-
sociation among FOXP1, BCL2, and BCL6, 
which would indicate the processes in diffuse 
large B-cell lymphoma tumor cells. The pres-
ence of FOXP3 positive cells and their associ-
ation with prognostic markers and/or gene ab-
normalities in tumor cells was also explored.
Patients and methods
Patients
We have analyzed 53 samples of formalin-fixed 
paraffin-embedded lymph nodes taken at the 
time of a diagnosis from patients with de novo  
diffuse large B-cell lymphoma. The patients 
were 25 women and 28 men with median age 
of 66 years (range, 23-91). The diagnoses were 
made by pathologists from the Department of 
Pathology and Cytology, Merkur University 
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Hospital according to the World Health Or-
ganization criteria (1).
This study is a part of a research project ap-
proved by the Ethics Committee of the Zagreb 
University School of Medicine.
Methods
Immunostaining. Immunostaining was per-
formed on 4 μm-thick formalin-fixed paraf-
fin-embedded lymph nodes sections using the 
LSAB/HRP kit (Dako, Glostrup, Denmark), 
according to the manufacturer’s instructions. 
The JC12 anti-FOXP1 and 236A/E7 anti-
FOXP3 antibodies were acquired from Dr Al-
ison Banham, Oxford, UK; BCL2-124 from 
the LRF Immunodiagnostics Unit, Oxford, 
UK; and BCL6 from Dako.
Cases with more than 30% of positive tu-
mor cells were considered positive. FOXP1 
staining intensity was graded as weak (+), 
moderate (++), or strong (+++).
All cases with at least some FOXP3-posi-
tive cells were scored as positive for the pres-
ence of Tregs cells.
Diffuse large B-cell lymphomas were di-
vided into GC or ABC types according to the 
method described by Hans et al (4).
Fluorescent in situ hybridization. Fluores-
cent in situ hybridization (FISH) was per-
formed according to the protocol described 
by Ventura et al (25). Abnormalities of the 
FOXP1 gene were detected with a break-apart 
probe (26), abnormalities of BCL2 gene with 
a dual color fusion probe (Vysis, Downer’s 
Grove, IL, USA), and abnormalities of BCL6 
gene with a break-apart probe (Vysis). Cut-off 
values for each FISH probe were determined 
on 5 sections of non-tumor formalin-fixed 
paraffin-embedded lymph nodes. Cut-off val-
ues for all probes were first found to be in the 
range between 5% and 7% of tumor cells in a 
sample with any of the investigated abnormal-
ities (FOXP1 probe 6.3%, BCL2 probe 5.2%; 
BCL6 probe 6.9%) and then the value was es-
timated to be 7%.
Statistical analysis
Differences between the groups were tested 
using χ2 test (Statistical Package for the So-
cial Sciences for Windows, version 14.0; SPSS 
Inc., Chicago, IL, USA). The level of statistical 
significance was set at 0.05.
Results
Immunostaining
BCL2 and BCL6 protein were expressed in 37 
and 17 diffuse large B-cell lymphoma cases, re-
spectively (Figure 1D and 1E). Both proteins 
were expressed in tumor cells of all positive 
samples with approximately same intensi-
ty. FOXP1 protein was expressed in 28 cases 
(Figure 1F), with weak staining observed in 10 
cases, moderate staining in 7 cases, and strong 
staining in 11 cases (Table 1). FOXP3 posi-
tive infiltrating lymphocytes were found in 37 
cases. There were 1%-10% of FOXP3 positive 
cells in the whole tumor section area in 31 cas-
es and more than 30% of FOXP3 positive cells 
in 6 cases.
Two or more of the investigated proteins 
were expressed in the same case of diffuse 
large B-cell lymphoma (FOXP1 and BCL2 in 
15 cases; FOXP1 and BCL6 in 3 cases; and 
FOXP1, BCL2, and BCL6 in 5 cases). Seven 
cases were negative for all the investigated pro-
teins.
Fluorescent in situ hybridization
BCL2 locus abnormalities were observed 
in 15 cases (Figure 1A). The abnormalities 
were as follows: 5 cases of translocations (five 
2F1R1G), 8 cases of amplifications/aneusomy 
(one 5R2G; seven 3R2G), and 2 cases of both 
translocation and amplification/aneusomy 
(one 2F2R1G; one 2F3R1G). BCL6 abnor-
malities were observed in 26 cases, as follows 
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(Figure 1B): 7 cases of translocations (seven 
1F1R1G), 14 cases of amplifications/aneuso-
my (eight 3F; four 4F; two >5F), and 5 cases 
of both translocation and amplification/aneu-
somy (four 2F1R1G; one 3F1R1G). No dif-
ferentiation was made between amplifications 
and aneusomy. Only a single case showed 
a split in the FOXP1 locus (one 1F1R1G), 
and additional gene copies/aneusomy of the 
FOXP1 probe were seen in 18 cases (13 3F,3 
4F,2 5F) (Table 2, Figure 1C). The case with a 
split in the FOXP1 locus was checked for IGH 
translocation with an IGH break-apart probe 
(Vysis) and showed a split signal, indicating 
the presence of FOXP1/IGH translocation.
More than one gene abnormality was ob-
served in 17 cases as follows: BCL2 and BCL6 
in 1 case, FOXP1 and BCL2 in 1 case, FOXP1 
and BCL6 in 6 cases, and FOXP1, BCL2, and 
BCL6 in 9 cases.
FOXP1 gene abnormalities were usually 
present together with BCL6 gene abnormali-
ties (χ21 = 8.497, P = 0.004). A significant asso-
ciation was also observed between the absence 
Table 1. Immunostaining of BCL2, BCL6, and FOXP1 proteins in 
tumor cells of 53 patients with diffuse large B-cell lymphoma
Immunostaining
Protein positive negative not informative
BCL2 32 21 0
BCL6 17 36 0
FOXP1:* 28
 weak 10
 medium  7
 strong 11
*Staining was defined as weak (+), medium (++), and strong (+++) (7,8).
Table 2. BCL2, BCL6, and FOXP1 gene abnormalities in tumor 
cells of 53 patients with diffuse large B-cell lymphoma
Gene
Abnormality BCL2 BCL6 FOXP1
No abnormality 35 25 30
Translocation  5  7  1
Additional gene copies  8 14 18
Translocation + additional gene copies  2  5  0
Not informative  3  2  4
Total 53 53 53
Table 3. Intensity of FOXP1 protein expression in relation to 
FOXP1 gene abnormalities in 28 patients with FOXP1-positive 
diffuse large B-cell lymphoma
FOXP1 gene
FOXP1 protein staining* normal >2 gene copies not informative
Weak 7 3 0
Moderate 3 4 0
Strong 3 6 2
*Staining was defined as weak (+), medium (++), and strong (+++) (7,8).
Figure 1. Fluorescent in situ hybridization and immunostaining slides 
of diffuse large B-cell lymphoma tumor samples. (D) BCL2 immunos-
taining; (E) BCL6 immunostaining; (F) FOXP1 immunostaining; (A) 
IGH/BCL2 translocation (2F1R1G); (B) BCL6 translocation (1F1R1G); 
(C) additional FOXP1 gene copy (3F).
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of FOXP1 gene abnormalities and the presence 
of BCL2 gene abnormalities (χ21 = 10.394, 
P = 0.001).
Association between genetic abnormalities and 
protein expression
Cases without FOXP1 gene abnormalities 
showed either the presence or absence of ex-
pression of BCL2 protein. However, cas-
es with FOXP1 gene abnormality showed 
the expression of BCL2 protein (χ21 = 5.858, 
P = 0.016). A significant association between 
FOXP1 gene abnormalities and FOXP1 pro-
tein expression level was also observed. When 
no gene abnormalities were observed, there 
was no deregulation of protein expression. 
Conversely, in cases showing a FOXP1 trans-
location or additional gene copy, FOXP1 pro-
tein was overexpressed (χ22 = 7.157, P = 0.028) 
(Table 3).
When there was no BCL2 gene aberration, 
the BCL2 protein was or was not expressed, 
but when there was IGH/BCL2 translocation 
or additional BCL2 gene copy, BCL2 protein 
was usually expressed (χ21 = 6.349, P = 0.012).
There was no significant association be-
tween GC and ABC immunophenotype and 
abnormalities of FOXP1, either at the genetic 
or protein level.
There was no association between the pres-
ence of FOXP3 positive cells and GC or ABC 
type. There were also no significant associa-
tions between FOXP3 positivity and any of 
the analyzed diffuse large B-cell lymphoma 
prognostic markers and between different per-
centages of FOXP3 positive cells in the sam-
ples and BCL2, BCL6, and FOXP1 protein 
expression or their gene abnormalities.
Discussion
Our group of diffuse large B-cell lymphoma 
patients showed additional copy of FOXP1 
gene in 36.7% of cases (18 of 49 samples ade-
quate for interpretation) and FOXP1 protein 
expression in 58% of cases (28 of 50 samples 
adequate for interpretation), similar to previ-
ously published diffuse large B-cell lymphoma 
data (4,8,27). FOXP3 positive cells were de-
tected in 37 cases.
Cases with positive FOXP1 expression had 
varying immunostaining intensities, as was ex-
pected (10,15). There was a significant associ-
ation between FOXP1 gene abnormality and 
protein levels – when there were no gene ab-
normalities, protein expression was present 
as weak immunostaining intensity and when 
there was an additional gene copy, protein ex-
pression was present as moderate/strong stain-
ing. It is possible that cases with additional 
gene copies or even chromosome 3 gains are 
actively transcribing FOXP1 and thus yield-
ing higher amounts of protein through gene 
dosage effects, although this is not the only 
known mechanism of FOXP1 expression 
(de)regulation (27,28).
Only a single case showed FOXP1 trans-
location. Besides that it also showed IGH 
translocation, thus possibly forming the 
FOXP1/IGH translocation. This case showed 
no FOXP1 expression, since the total count 
of FOXP1 positive tumor cells was lower 
than 30%, suggesting that overexpression of 
FOXP1 protein is not necessarily a result of 
gene rearrangement (27,29). This was a mor-
phologically clear case of diffuse large B-cell 
lymphoma which had no BCL2 and/or BCL6 
translocations or additional gene copies.
A significant association was found be-
tween the presence of FOXP1 and BCL6 gene 
abnormalities. When there was an addition-
al copy of one of these genes, there was also an 
additional copy of the other. Since both these 
genes are located on chromosome 3, this is 
most likely a result of the aneusomy of chro-
mosome 3 (1).
The association between FOXP1 and 
BCL2 gene abnormalities requires further in-
Korać and Dominis: Prognostic Markers in Diffuse Large B-cell Lymphoma
623
vestigation to discover the mechanism under-
lying this phenomenon. According to our re-
sults, if there is no change on one gene there 
will be no change on the other gene. How-
ever, if there is additional FOXP1 gene copy 
then BCL2 protein will be expressed. This 
finding is contradictory to the previously de-
scribed BCL2 and FOXP1 association in dif-
fuse large B-cell lymphoma (7) and might be a 
result of the small number of cases studied in 
our study.
BCL2 gene abnormalities (both translo-
cations and additional copy numbers) appear 
together with BCL2 protein expression, sug-
gesting that BCL2 expression in diffuse large 
B-cell lymphoma is regulated by translocations 
or copy number changes. IGH/BCL2 translo-
cation has been recognized as a cause for con-
stitutive expression of BCL2 protein in fol-
licular lymphoma and has been found also in 
diffuse large B-cell lymphoma (30,31).
We did not find any significant association 
between GC and ABC group and changes in 
FOXP1 gene/protein. This differs from a pre-
vious study (7) and suggests that the division 
of diffuse large B-cell lymphoma based on the 
tumor cells origin detected by immunohisto-
chemistry is not informative enough, similar 
to morphological division (1).
FOXP3 expression, indicating the presence 
of Tregs in a tumor tissue, was also observed, 
but it did not show any significant association 
with BCL2, BCL6, and FOXP1. This observa-
tion also applies to the abnormalities involving 
BCL2, BCL6, and FOXP1 genes.
Considering FOXP3 positive cells in our 
diffuse large B-cell lymphoma group, we found 
no relation between them and any of the ana-
lyzed prognostic markers. This suggests a need 
for further studies that will investigate wheth-
er regulatory T cells have any impact on the 
processes that take place in diffuse large B-cell 
lymphoma tumor cells.
In conclusion, the results obtained on 53 
patients from the Merkur University Hospital 
showed that there was an association between 
FOXP1 and BCL2 in diffuse large B-cell lym-
phoma patients, but their presence was not re-
lated to GC or ABC lymphoma subgroups. 
FOXP3-positive T lymphocytes in these enti-
ties were present, but their impact on events 
in B tumor cells is still not clear.
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